Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 7, keine Gesamtzahl für „Riximyo“
Suchtreffer
Begriffe & Kennungen
Riximyo · 4.8 · Table 7 Adverse reactions in rituximab-treated PV patients PV Study 1 (up to Month 24) and PV Study 2 (up to W
Eintrag öffnenRiximyo · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenRiximyo · 4.8 · Tabulated list of adverse reactions for PV Studies 1 and 2, or during post-marketing surveillance
Eintrag öffnenRiximyo · 4.8 · The adverse reactions from GPA/MPA Study 1 listed in Table 5 with a frequency categorisation of "common" or "v
Eintrag öffnenRiximyo · 4.8 · The adverse reactions from PV Studies 1 and 2 with a frequency categorisation of "common" or "very common" are
Eintrag öffnenRiximyo · 4.8 · The adverse reactions identified only during post-marketing surveillance, and for which a frequency could not
Eintrag öffnenRiximyo · 4.8 · The following terms have been reported as adverse reactions during clinical trials, however, were reported at
Eintrag öffnenRiximyo · 4.8 · The frequencies of adverse reactions reported with rituximab alone or in combination with chemotherapy are sum
Eintrag öffnenRiximyo · 4.8 · The most common infusion-related reaction symptoms/Preferred Terms for PV Study 2 were dyspnoea, erythema, hyp
Eintrag öffnenRiximyo · 4.8 · The most commonly reported events considered as adverse reactions were infusion-related reactions and infectio
Eintrag öffnenRiximyo · 4.8 · The most frequent adverse reactions considered due to receipt of rituximab IRRs. The overall incidence of IRRs
Eintrag öffnenRiximyo · 4.8 · The most frequently observed adverse reactions in patients receiving rituximab were IRRs which occurred in the
Eintrag öffnenRiximyo · 4.8 · The most frequently reported or observed serious adverse reactions were: • IRRs (including cytokine-release sy
Eintrag öffnenRiximyo · 4.8 · The overall safety profile of rituximab in adult and paediatric GPA/MPA patients is based on data from patient
Eintrag öffnenRiximyo · 4.8 · The overall safety profile of rituximab in non-Hodgkin’s lymphoma and CLL is based on data from patients from
Eintrag öffnenRiximyo · 4.8 · The overall safety profile of rituximab in rheumatoid arthritis is based on data from patients from clinical t
Eintrag öffnenRiximyo · 4.8 · The overall safety profile was consistent with the well-established safety profile for rituximab in approved a
Eintrag öffnenRiximyo · 4.8 · The safety profile of rituximab in PV was consistent with the established safety profile in other approved aut
Eintrag öffnenRiximyo · 4.8 · The safety profile of rituximab in combination with short-term, low-dose glucocorticoids in the treatment of p
Eintrag öffnenRiximyo · 4.8 · The safety profile of rituximab in paediatric GPA or MPA patients was consistent in type, nature and severity
Eintrag öffnen